← Leaderboards
Gregory P Adams
Fox Chase Cancer Center
$4,024,285
Attributed
$4,024,285
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–11$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$4,024,285 · 3
By mechanism
P50$1,955,622 · 1
R01$1,555,663 · 1
R21$513,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Louis M Weiner$35,160,146
- Joanne F Dorgan$8,245,231
- Brian William Smith$244,263
- Denise C Connolly$4,562,794
Others in their field
Top investigators on “Erbb2 Gene”
- Norman Wolmark · Nsabp Foundation, Inc.$43,988,954
- Charles M Perou · Univ Of North Carolina Chapel Hill$10,910,346
- Ellen M Velie · Michigan State University$10,395,017
- Leslie Bernstein · University Of Southern California$10,393,428
- Lewis A Chodosh · University Of Pennsylvania$10,338,684
- Carlos L Arteaga · Vanderbilt University$9,797,101
Research focus
Erbb2 GeneAffinityIn VivoBaseCellsPropertyTumorAntibodiesMalignant NeoplasmsImmunodeficient MouseNeoplastic CellAntigensAntigen TargetingMutantBlood VesselsMouse ModelPublic Health Medicine (Field)Binding (Molecular Function)Solid NeoplasmEngineeringAffectBiodistributionNormal Tissue MorphologyTranslating
Grant awards (13)
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$305,975
R01 · FY2011 · CA · contact PI
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$315,438
R01 · FY2010 · CA · contact PI
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$311,607
R01 · FY2009 · CA · contact PI
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors$171,000
R21 · FY2009 · CA · contact PI
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$733,901
P50 · FY2008 · CA · contact PI
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$311,607
R01 · FY2008 · CA · contact PI
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors$171,000
R21 · FY2008 · CA · contact PI
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$899,748
P50 · FY2007 · CA · contact PI
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$311,036
R01 · FY2007 · CA · contact PI
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors$171,000
R21 · FY2007 · CA · contact PI
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$106,581
P50 · FY2006 · CA · contact PI
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$128,658
P50 · FY2005 · CA
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$86,734
P50 · FY2004 · CA